Comparative Pharmacology
Head-to-head clinical analysis: INTAL versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTAL versus OLOPATADINE HYDROCHLORIDE.
INTAL vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer